Clinical trials: Canthal Lines
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Recombinant Collagen Freeze-Dried Fibre for Upper Facial Wrinkles
The goal of this clinical trial was to learn whether a collagen filler improved facial wrinkles. The study product was injectable recombinant collagen freeze-dried fibers.
- Trial name
- NCT07897773
- Testing
- Recombinant Collagen Freeze-Dried Fibers, Collagen Implant
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Shaanxi Giant Biotechnology Co., Ltd
Lateral Canthal Lines, Crows Feet
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
The purpose of this study is to confirm the effect of ANT-1401 in the treatment of Lateral Canthal Lines.
- Trial name
- NCT01809964
- Testing
- ANT-1401, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Skin Roughness, Wrinkle
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
- Conditions
- Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
- Trial name
- NCT04540900
- Testing
- KB301
- Where
- 4 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Krystal Biotech, Inc.
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Longitudinal Evaluation and Real-world Evidence of NT201
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A…
- Trial name
- NCT05222607
- Testing
- IncobotulinumtoxinA
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Merz North America, Inc.
Lateral Canthal Lines, Perioral Rhytids
Princess® RICH for the Correction of Fine Lines
Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline…
- Trial name
- RICH (NCT03923634)
- Testing
- Princess® RICH
- Where
- 3 sites in Austria
- Volunteers
- 102 people
- Sponsor
- Croma-Pharma GmbH
Lateral Canthal Lines, Crow's Feet
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called crow's feet, also known as…
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT01064518
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Canthal Lines
A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
This double-blind study has two parts for each subject (same population): Part A: initial treatment in Lateral Canthal Lines (LCL) (placebo-controlled): To assess the efficacy and safety of Azzalure® compared to placebo in the…
- Trial name
- NCT01308060
- Testing
- Botulinum Toxin Type A
- Volunteers
- 335 people
- Sponsor
- Galderma R&D
Lateral Canthal Lines
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
- Trial name
- NCT03911102
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines, Lateral Canthal Lines
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
- Trial name
- READY-4 (NCT04225260)
- Testing
- botulinum toxin neuromodulator
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Facial Rhytides, Glabellar Rhytides
A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
This is a safety and efficacy study of onabotulinumtoxinA in subjects with upper facial rhytides (forehead lines, glabellar lines, lateral canthal lines [crow's feet lines]).
- Trial name
- NCT02261493
- Testing
- OnabotulinumtoxinA, Normal Saline
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 787 people
- Sponsor
- Allergan
Glabellar Frown Lines, Canthal Lines
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
This study to assess aesthetic improvement following treatment with QM1114-DP.
- Trial name
- NCT05148000
- Testing
- QM1114-DP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA II (NCT04622254)
- Testing
- NT 201
- Where
- 12 sites in Germany
- Volunteers
- 368 people
- Sponsor
- Merz North America, Inc.
Lateral Canthal Lines, Crow's Feet
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
The purpose of this study is to find out if an investigational drug, called RT001 Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet…
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT01124552
- Testing
- RT001 Botulinum toxin type A (Dose A), RT001 Botulinum Toxin Type A (Dose B), Vehicle
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, Glabellar Lines
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.
- Trial name
- NCT03732833
- Testing
- MT10109L
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 425 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- Trial name
- READY-3 (NCT04247074)
- Testing
- botulinum toxin neuromodulator
- Where
- 12 sites in United States, Canada
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03655691
- Testing
- Vehicle, botulinum toxin, Type A
- Where
- 6 sites in United States
- Volunteers
- 79 people
- Sponsor
- Eirion Therapeutics Inc.
Upper Facial Lines
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), lateral canthal lines (LCL), and forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities…
- Trial name
- UFL BOND 974 (NCT06218251)
- Testing
- BOTOX
- Where
- 10 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Lateral Canthal Lines
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
This phase 2 study includes two treatment period; 1)Dose- ranging period, Day 0 to 16 weeks, which will assess dose-related safety/tolerance, and the potential to improve the appearance of lateral canthal lines and 2) open-label…
- Trial name
- NCT04143854
- Testing
- MBA-P01(Botulinum toxin A)
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines, Crow's Feet
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.
- Trial name
- NCT01358695
- Testing
- ANT-1207, Botulinum Toxin, Type A, Botulinum Toxin Type A
- Where
- 6 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Lateral Canthal Lines
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.
- Trial name
- NCT00884234
- Testing
- Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.